EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence

Fatemeh Moosavi, Bahareh Hassani, Somayeh Nazari, Luciano Saso, Omidreza Firuzi

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024-11 · 1879 (6) · 189185

DOI: 10.1016/j.bbcan.2024.189185 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024-11. Verfasst von Fatemeh Moosavi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Pancreatic Ductal, DNA Damage, Pancreatic Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 259 Literaturangaben. Gefördert von: Shiraz University of Medical Sciences Vice Chancellor of Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is associated with one of the most unfavorable prognoses across all malignancies. In this review, we investigate the role of inhibitors targeting crucial regulators of DNA damage response (DDR) pathways, either as single treatments or in combination with chemotherapeutic agents and targeted therapies in PDAC. The most prominent clinical benefit of PARP inhibitors' monotherapy is related to the principle of synthetic lethality in individuals harboring BRCA1/2 and other DDR gene mutations as predictive biomarkers. Moreover, induction of BRCAness with inhibitors of RTKs, including VEGFR and c-MET and their downstream signaling pathways, RAS/RAF/MEK/ERK and PI3K/AKT/mTOR in order to expand the application of PARP inhibitors in patients without DDR mutations, has also been addressed. Other DDR-targeting agents beyond PARP inhibitors, including inhibitors of ATM, ATR, CHEK1/2, and WEE1 have also demonstrated their potential in preclinical models of PDAC and may hold promise in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Pancreatic DuctalDNA DamagePancreatic NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsAnimalsHumansDNA RepairMolecular Targeted TherapySignal Transduction

Stichwörter der Autor:innen

Gastrointestinal tumorsKinase inhibitorsPancreatic cancerPersonalized medicineSynthetic lethality

Substanzen

Antineoplastic AgentsPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, P. le Aldo Moro 5, 00185 Rome, Italy.
  • Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: firuzio@sums.ac.ir.

Förderung

  • Shiraz University of Medical Sciences Vice Chancellor of Research

Zitieren

APA

Moosavi, F., Hassani, B., Nazari, S., Saso, L., & Firuzi, O. (2024). Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1879(6), 189185. https://doi.org/10.1016/j.bbcan.2024.189185

Vancouver

Moosavi F, Hassani B, Nazari S, Saso L, Firuzi O. Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(6):189185. doi:10.1016/j.bbcan.2024.189185

BibTeX
@article{Moosavi2024,
  author = {Moosavi, Fatemeh and Hassani, Bahareh and Nazari, Somayeh and Saso, Luciano and Firuzi, Omidreza},
  title = {Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2024},
  volume = {1879},
  number = {6},
  pages = {189185},
  doi = {10.1016/j.bbcan.2024.189185}
}
Kostenlos starten →